Axsome Therapeutics

Member

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. Axsome delivers scientific breakthroughs by identifying critical gaps in care and develops differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Axsome’s industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Axsome is on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit www.axsome.com.